目的 :制备葡萄球菌B型肠毒素 (SEB)突变体 ,观察其抗肿瘤活性变化。方法 :将诱导表达的SEB突变体重组蛋白包涵体进行变性复性和分离纯化 ,并对其肿瘤抑制活性与野生型SEB进行比较。观察突变体蛋白的抑瘤效果。结果 :建立了可行的包涵体复性条件和纯化方法 ,获得的突变体蛋白具有明显的抗肿瘤作用 ,其抑瘤活性比野生型SEB至少高 10倍。结论 :获得的突变体SEB K172E的抗肿瘤效果经体外实验证实优于野生型SEB ,有可能成为一种较具潜力的抗肿瘤药物 Objective: To prepare the staphylococcal enterotoxin B (SEB) mutant and observe its antitumor activity. Methods: The recombinant protein inclusion bodies of SEB mutant induced by expression were denatured, renaturated and purified. The tumor inhibitory activity was compared with wild-type SEB. Observe the inhibitory effect of the mutant protein. Results: The feasibility and purification method of inclusion body were established. The obtained mutant protein had obvious antitumor activity, and its antitumor activity was at least 10 times higher than that of wild-type SEB. Conclusion: The antitumor effect of mutant SEB K172E obtained by in vitro experiments confirmed superior to wild-type SEB, it may become a potential antitumor drug